Novo Nordisk, the maker of weight loss drug Wegovy, will lay off about 9,000 people as it grapples with rising competition in ...

Eli Lilly (LLY) recently announced positive results from its Phase 3 BRUIN CLL-313 trial, revealing significant ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's approved blood cancer therapy Jaypirca helped delay progression of the disease in previously untreated patients ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

The restructuring, which would eliminate 11% of the company's workforce, aimed to reduce organizational complexity and speed ...

Insitro, Firefly Bio and Superluminal Medicines are among the first participants in Lilly’s “TuneLabs” platform, which the pharma says can help young drugmakers while training its own models.

Eli Lilly is inviting early-stage biotechs to make use of drug discovery models that the pharma is providing via a new AI platform. | Eli Lilly is inviting early-stage biotechs to make use of drug ...

Eli Lilly dominates obesity and diabetes treatments with soaring tirzepatide sales and promising oral drug data. Find out why ...

New data from Eli Lilly says its daily, oral GLP-1 pill may help people who have obesity and people who have Type 2 diabetes lose a significant amount of weight.

Tribeca Studios has launched a new incubator program, which aims to empower rising filmmakers to more earnestly portray diseases and health-related stories on-screen. Tribeca created the program in ...

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 13.4% ...